What is Bio-Path Hldgs Inc's earnings per share (EPS)?

Bio-Path Hldgs Inc (BPTH) reported diluted earnings per share of $-4.12 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bio-Path Hldgs Inc Financials

BPTH

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Bio-Path Hldgs Inc (BPTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BPTH FY2024 2026-04-22

Bio-Path remains a capital-funded development business, with fresh financing replacing operating cash burn more than building balance-sheet strength.

In FY2024, financing cash flow of $10.7M almost exactly offset operating cash outflow of $10.6M, yet year-end cash was only $1.2M and equity just $154K. That combination shows the lower loss did not materially strengthen the company’s finances, because new capital was largely consumed just to keep operations running.

The move from a -$16.1M net loss in FY2023 to -$9.9M in FY2024 came alongside R&D falling from $11.6M to $7.3M, so the improvement looks tied mainly to reduced development spending rather than a new source of self-sustaining earnings. Cash burn and net loss stayed broadly aligned, which means the accounting loss mostly reflects real cash use.

The balance sheet has gone from cash-rich in FY2020 to thinly cushioned in FY2024: cash fell from $13.8M to $1.2M, and the current ratio compressed from 13.6x to 1.1x. With liabilities at $3.7M against only $154K of equity and no meaningful revenue base reported, the operating model currently depends on repeated external funding rather than internally generated resources.

Financial Health Signals

Financial Profile 3/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bio-Path Hldgs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Bio-Path Hldgs Inc has elevated debt relative to equity (D/E of 24.21), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Bio-Path Hldgs Inc's current ratio of 1.15 is below the typical benchmark, resulting in a score of 18/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Returns

Bio-Path Hldgs Inc generates a -6424.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -3645.8% the prior year.

Piotroski F-Score Weak

1/9

Bio-Path Hldgs Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.07x

For every $1 of reported earnings, Bio-Path Hldgs Inc generates $1.07 in operating cash flow (-$10.6M OCF vs -$9.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$11.9M

YoY+24.2%

Bio-Path Hldgs Inc's EBITDA was -$11.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.2% from the prior year.

Net Income

-$9.9M

YoY+38.5%

Bio-Path Hldgs Inc reported -$9.9M in net income in fiscal year 2024. This represents an increase of 38.5% from the prior year.

EPS (Diluted)

$-4.12

Bio-Path Hldgs Inc earned $-4.12 per diluted share (EPS) in fiscal year 2024. This represents an increase of 87.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.2M

YoY+11.5%

5Y CAGR-43.5%

10Y CAGR-21.9%

Bio-Path Hldgs Inc held $1.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Bio-Path Hldgs Inc had 6M shares outstanding in fiscal year 2024. This represents an increase of 833.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-6424.7%

YoY-2778.9pp

5Y CAGR-6383.9pp

10Y CAGR-6394.4pp

Bio-Path Hldgs Inc's ROE was -6424.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 2778.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$7.3M

YoY-37.2%

5Y CAGR+9.7%

10Y CAGR+16.2%

Bio-Path Hldgs Inc invested $7.3M in research and development in fiscal year 2024. This represents a decrease of 37.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BPTH Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.3M-37.2%	$11.6M+26.7%	$9.2M+55.1%	$5.9M-10.2%	$6.6M+43.5%	$4.6M
SG&A Expenses	$4.7M+10.9%	$4.2M-10.6%	$4.7M+4.5%	$4.5M+4.7%	$4.3M+5.4%	$4.1M
Operating Income	-$12.0M+24.3%	-$15.8M-14.0%	-$13.9M-33.1%	-$10.4M+4.3%	-$10.9M-25.5%	-$8.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$9.9M+38.5%	-$16.1M-15.9%	-$13.9M-32.8%	-$10.4M+4.1%	-$10.9M-26.5%	-$8.6M
EPS (Diluted)	$-4.12	$-33.63+11.8%	$-38.12	$-1.55+45.2%	$-2.83	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$275K	N/A	$2.0M	N/A	$1.3M-29.7%	$1.9M-18.1%	$2.3M	N/A
SG&A Expenses	$213K-58.6%	$514K-59.3%	$1.3M	N/A	$1.3M+13.0%	$1.2M-17.2%	$1.4M	N/A
Operating Income	-$488K	N/A	-$3.2M	N/A	-$2.6M+13.3%	-$3.0M+17.8%	-$3.7M	N/A
Interest Expense	N/A	$35K+600.0%	$5K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$976K	N/A	-$2.9M	N/A	-$2.1M-13.2%	-$1.9M+40.8%	-$3.2M	N/A
EPS (Diluted)	$-0.11+80.0%	$-0.55-37.5%	$-0.40	N/A	$-0.70+39.7%	$-1.16	$-4.88	N/A

BPTH Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.9M+20.6%	$3.2M-79.8%	$16.0M-39.9%	$26.6M+61.3%	$16.5M-27.3%	$22.7M
Current Assets	$3.8M+24.1%	$3.0M-80.5%	$15.6M-40.3%	$26.1M+63.8%	$16.0M-27.4%	$22.0M
Cash & Equivalents	$1.2M+11.5%	$1.1M-89.9%	$10.4M-56.3%	$23.8M+72.8%	$13.8M-32.7%	$20.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.7M+34.2%	$2.8M+54.6%	$1.8M+61.7%	$1.1M-20.9%	$1.4M-10.7%	$1.6M
Current Liabilities	$3.3M+72.9%	$1.9M+13.2%	$1.7M+75.8%	$958K-18.0%	$1.2M-6.0%	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$154K-65.1%	$441K-96.9%	$14.2M-44.3%	$25.5M+68.9%	$15.1M-28.5%	$21.1M
Retained Earnings	-$117.5M-9.2%	-$107.6M-17.6%	-$91.5M-17.9%	-$77.7M-15.5%	-$67.2M-19.3%	-$56.3M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$690K-7.5%	$746K-66.0%	$2.2M-43.5%	$3.9M+31.0%	$3.0M-42.1%	$5.1M+189.5%	$1.8M-45.1%	$3.2M
Current Assets	$663K-2.5%	$680K-67.9%	$2.1M-43.9%	$3.8M+30.3%	$2.9M-42.2%	$5.0M+206.6%	$1.6M-46.2%	$3.0M
Cash & Equivalents	$0	$0-100.0%	$122K-89.6%	$1.2M+108.7%	$562K-86.0%	$4.0M+2030.9%	$188K-82.1%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.7M+10.0%	$7.9M+65.2%	$4.8M+28.3%	$3.7M+1.4%	$3.7M-3.9%	$3.8M-12.9%	$4.4M+58.1%	$2.8M
Current Liabilities	$8.7M+10.4%	$7.9M+65.8%	$4.7M+44.0%	$3.3M-2.4%	$3.4M+12.1%	$3.0M-21.0%	$3.8M+100.0%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$8.0M-11.8%	-$7.2M-176.5%	-$2.6M-1781.2%	$154K+121.6%	-$712K-155.2%	$1.3M+149.2%	-$2.6M-695.2%	$441K
Retained Earnings	-$125.9M-0.8%	-$125.0M-3.8%	-$120.4M-2.4%	-$117.5M-2.4%	-$114.7M-1.9%	-$112.6M-1.7%	-$110.8M-2.9%	-$107.6M

BPTH Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$10.6M+8.3%	-$11.5M+23.6%	-$15.1M-52.3%	-$9.9M+9.5%	-$11.0M-31.1%	-$8.4M
Capital Expenditures	N/A	N/A	$21K-70.0%	$70K	N/A	$0
Free Cash Flow	N/A	N/A	-$15.1M-51.4%	-$10.0M	N/A	-$8.4M
Investing Cash Flow	N/A	N/A	-$21K+70.0%	-$70K	N/A	$0
Financing Cash Flow	$10.7M+385.5%	$2.2M+27.0%	$1.7M-91.3%	$20.0M+366.4%	$4.3M-84.6%	$27.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	$0+100.0%	-$283K+78.4%	-$1.3M+54.4%	-$2.9M+16.0%	-$3.4M+19.6%	-$4.3M-311.0%	-$1.0M+42.8%	-$1.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0-100.0%	$161K-38.5%	$262K-92.5%	$3.5M+21925.0%	-$16K-100.2%	$7.2M+4049.4%	$174K-66.1%	$514K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BPTH Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-6424.7%-2778.9pp	-3645.8%-3548.0pp	-97.8%-56.8pp	-41.0%+31.2pp	-72.2%-31.4pp	-40.8%
Return on Assets	-254.8%+244.5pp	-499.3%-412.5pp	-86.8%-47.5pp	-39.3%+26.7pp	-66.0%-28.1pp	-38.0%
Current Ratio	1.15-0.5	1.60-7.7	9.27-18.0	27.29+13.6	13.65-4.0	17.68
Debt-to-Equity	24.21+17.9	6.30+6.2	0.13+0.1	0.04-0.0	0.09+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-144.8%	N/A	N/A
Return on Assets	-141.5%	N/A	-129.9%	N/A	-71.3%-34.8pp	-36.5%+142.0pp	-178.6%	N/A
Current Ratio	0.08-0.0	0.09-0.4	0.45-0.7	1.15+0.3	0.86-0.8	1.67+1.2	0.43-1.2	1.60
Debt-to-Equity	-1.09+0.0	-1.10+0.7	-1.85-26.1	24.21+29.4	-5.16-8.1	2.96+4.6	-1.67-8.0	6.30
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Regen Biopharma RGBP

$85K

Hepion Pharmaceuticals Inc HEPA

$4.3M

LadRx LADX

$579K

Therapeutic Solutions Intl Inc TSOI

$512K

AIBotics AIBT

$397K

Frequently Asked Questions

Is Bio-Path Hldgs Inc profitable?

No, Bio-Path Hldgs Inc (BPTH) reported a net income of -$9.9M in fiscal year 2024.

What is Bio-Path Hldgs Inc's EBITDA?

Bio-Path Hldgs Inc (BPTH) had EBITDA of -$11.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bio-Path Hldgs Inc's return on equity (ROE)?

Bio-Path Hldgs Inc (BPTH) has a return on equity of -6424.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Bio-Path Hldgs Inc's operating cash flow?

Bio-Path Hldgs Inc (BPTH) generated -$10.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bio-Path Hldgs Inc's total assets?

Bio-Path Hldgs Inc (BPTH) had $3.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Bio-Path Hldgs Inc spend on research and development?

Bio-Path Hldgs Inc (BPTH) invested $7.3M in research and development during fiscal year 2024.

How many shares does Bio-Path Hldgs Inc have outstanding?

Bio-Path Hldgs Inc (BPTH) had 6M shares outstanding as of fiscal year 2024.

What is Bio-Path Hldgs Inc's current ratio?

Bio-Path Hldgs Inc (BPTH) had a current ratio of 1.15 as of fiscal year 2024, which is considered adequate.

What is Bio-Path Hldgs Inc's debt-to-equity ratio?

Bio-Path Hldgs Inc (BPTH) had a debt-to-equity ratio of 24.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio-Path Hldgs Inc's return on assets (ROA)?

Bio-Path Hldgs Inc (BPTH) had a return on assets of -254.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Bio-Path Hldgs Inc's cash runway?

Based on fiscal year 2024 data, Bio-Path Hldgs Inc (BPTH) had $1.2M in cash against an annual operating cash burn of $10.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bio-Path Hldgs Inc's Piotroski F-Score?

Bio-Path Hldgs Inc (BPTH) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio-Path Hldgs Inc's earnings high quality?

Bio-Path Hldgs Inc (BPTH) has an earnings quality ratio of 1.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bio-Path Hldgs Inc?

Bio-Path Hldgs Inc (BPTH) scores 3 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.